Today’s Research Reports on Stocks to Watch: TapImmune and Intercept Pharmaceuticals

NEW YORK, NY / ACCESSWIRE / June 11, 2018 / TapImmune and Intercept Pharmaceuticals were two biotech stocks heading higher in Friday trading. TapImmune shares rocketed after receiving an upgrade from WBB Securities. Intercept didn’t have any particularly remarkable news but did announce that management would be presenting this Tuesday at the Goldman Sachs 39th Annual Global Healthcare Conference.

RDI Initiates Coverage on:

TapImmune, Inc.
https://www.rdinvesting.com/report/?ticker=TPIV

Intercept Pharmaceuticals, Inc.
https://www.rdinvesting.com/report/?ticker=ICPT

TapImmune, Inc. shares exploded in Friday trading, closing the day up 51.26% at $9.00 on colossal trading volume. The stock traded roughly 13.2 million shares compared to an average trading volume of around 382,000 shares. Shares elevated after the company received some encouraging words from a WBB Securities analyst. Analyst Steve Brozak with the firm upgraded TapImmune shares from “speculative buy” to “buy” and reiterated a $5.50 price target. Brozak noted, “We have previously commented in a note our continued interest in TPIV’s strategic move to merge with Marker, as the clinical assets carry data that cannot be overlooked, and the proposed management advisory, as well as directorship of the combined company place prominence on TPIV to be a leader in the cell therapy space.” It was not too long ago that TapImmune announced a merger agreement and reorganization with privately held Marker Therapeutics. Brozack added, “Using a sum-of-the parts valuation, we evaluate potential revenue streams from the TPIV200 ovarian cancer programs to be at $5 a share and marker product candidates derived from the MultiTAA platform to be $6 a share. With 12.8 million shares currently outstanding and twice that amount at closing, we arrive at a 12-month price target of $5.50.” The merger with Marker is expected to close in the second quarter.

Access RDI’s TapImmune, Inc. Research Report at:
https://www.rdinvesting.com/report/?ticker=TPIV

Intercept Pharmaceuticals, Inc. shares closed up 6.23% at $76.20 on roughly 1.6 million shares this past Friday. The biopharmaceutical company announced last week that management will be presenting at the Goldman Sachs 39th Annual Global Healthcare Conference on Tuesday, June 12, 2018. It was last month that the company released first quarter results. For the quarter, Intercept had a loss of $3.22 per share which topped Wall Street expectations that called for a loss of $3.41. The company’s CEO and President Mark Pruzanski, M.D. stated, “We are pleased with our progress to date in 2018, as we continue to work to strengthen our leadership position in NASH and remain on track for the top line readout of data from our Phase 3 REGENERATE trial in the first half of 2019. Based on our review of the evolving competitive landscape, the new data released at the recent International Liver Congress in Paris and the strength of OCA’s Phase 2 and other data, we continue to believe in OCA’s significant potential in NASH.” OCA, the company’s investigational therapy obeticholic acid, is currently the only FDA-designated Breakthrough Therapy in development for NASH, or nonalcoholic fatty liver disease.

Access RDI’s Intercept Pharmaceuticals, Inc. Research Report at:
https://www.rdinvesting.com/report/?ticker=ICPT

Our Actionable Research on TapImmune, Inc. (NASDAQ: TPIV) and Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com

ReleaseID: 502282